HCP Live October 1, 2023
Tim Smith

This study indicated the potential of PDLs as a strategy for those that have HDHP-HSAs to address both patient access and affordability of asthma care.

A preventative drug list (PDL) is linked with more affordable asthma medication as well as greater use of controller medication, according to recent findings, though PDLs do not lead to differences in outcomes for clinical asthma.1

This new data was the result of a recent case-control study which aimed to assess the effects of a PDL that provides exemption from out-of-pocket cost sharing for patients’ asthma medications on adverse outcomes, on their utilization, and on their out-of-pocket expenses.

The research was viewed as invaluable, given the varying results researchers have had in examining links between...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Survey / Study, Trends
Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
Does PBM Market Share Vary by Payer Type?
Allowing Medicare to Negotiate Drug Prices Remains Broadly Popular Among Voters, Though Most Are Unaware of the Law and Its Projected Savings
Pharma Pulse 9/13/24: AI Adoption for Clinical Trial Design, Comparing Biologics and Biosimilars & more

Share This Article